This inventor holds 6 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2015-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Scheesel, DE (2015 - 2024)
- Scheessel, DE (2018 - 2024)
Company Filing History:
Years Active: 2015-2025
Title: **Andreas Daiber: Innovator in Pharmaceutical Sciences**
Introduction
Andreas Daiber, an accomplished inventor based in Scheessel, Germany, has made significant contributions to the field of pharmaceutical sciences. With a total of five patents to his name, Daiber is at the forefront of developing treatments that address serious health conditions such as diabetes and cardiovascular diseases.
Latest Patents
Two of Daiber's latest patents focus on innovative compositions and methods involving SGLT-2 and DPP-4 inhibitors. The first patent details a pharmaceutical composition aimed at treating and preventing oxidative stress, particularly in patients with type 1 or type 2 diabetes. This invention highlights the potential of SGLT-2 inhibitors not only for glycemic control but also for reducing the risk of cardiovascular events in diabetic patients. The second patent revolves around vasoprotective and cardioprotective antidiabetic therapies, utilizing certain DPP-4 inhibitors to combat oxidative stress and endothelial dysfunction in both diabetic and non-diabetic patients.
Career Highlights
Andreas Daiber is currently affiliated with Boehringer Ingelheim International GmbH, a prominent player in the pharmaceutical industry. His work at the company showcases his commitment to advancing therapeutic options and improving patient outcomes in critical health areas.
Collaborations
Throughout his career, Daiber has collaborated with esteemed colleagues, including Hans-Juergen Woerle and Odd-Erik Johansen. These partnerships have facilitated the development of innovative solutions that address the complexities of metabolic and cardiovascular disorders.
Conclusion
Andreas Daiber's contributions to pharmaceutical innovation are noteworthy, particularly in the realm of diabetes management and cardiovascular health. His patents reflect a dedication to harnessing scientific advancements to improve the quality of life for patients worldwide. As he continues his work at Boehringer Ingelheim International GmbH, the impact of his innovations is poised to grow, potentially transforming therapeutic approaches in the medical community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile